STALEY CAPITAL ADVISERS’s Albany Molecular Research Inc AMRI Stock Holding History

STALEY CAPITAL ADVISERS’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-30,000	Closed	-$523K	–	132
2015 Q3	$523K	Hold	30,000	–	–	0.06%	77
2015 Q2	$607K	Hold	30,000	–	–	0.07%	75
2015 Q1	$528K	Hold	30,000	–	–	0.06%	77
2014 Q4	$488K	Hold	30,000	–	–	0.06%	77
2014 Q3	$662K	Hold	30,000	–	–	0.08%	70
2014 Q2	$604K	Hold	30,000	–	–	0.07%	76
2014 Q1	$558K	Buy	+30,000	New	+$413K	0.07%	76

Other funds holding AMRI

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OWP

Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return

VNIM

Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return

PIP

Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

ACM

American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

STALEY CAPITAL ADVISERS's AMRI Position: Q4 2015 in Review

STALEY CAPITAL ADVISERS sold out of Albany Molecular Research Inc (AMRI) in Q4 2015, closing a stake of 30,000 shares — an estimated $523K sold.

STALEY CAPITAL ADVISERS first reported a position in AMRI in Q1 2014 and held it in 7 quarters. The position peaked at $662K in Q3 2014. 151 funds tracked by Wall St. Rank hold AMRI as of Q4 2015.

STALEY CAPITAL ADVISERS reported no remaining Albany Molecular Research Inc position as of Q4 2015 after selling out during the quarter.
STALEY CAPITAL ADVISERS sold 30,000 Albany Molecular Research Inc shares in Q4 2015, an estimated $523K.
STALEY CAPITAL ADVISERS first reported a position in Albany Molecular Research Inc in Q1 2014 and held it in 7 quarters.
STALEY CAPITAL ADVISERS's Albany Molecular Research Inc position peaked at $662K in Q3 2014.
151 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q4 2015.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q4 2015, filed 5 Feb 2016.